Recent Investment Analysts’ Ratings Updates for Rezolute (RZLT)

Several brokerages have updated their recommendations and price targets on shares of Rezolute (NASDAQ: RZLT) in the last few weeks:

• 9/29/2026 – Rezolute was upgraded by Craig Hallum from “hold” to “buy”. They now have a $7.00 price target on the stock, up from $4.00.
• 9/25/2026 – Rezolute was upgraded by HSBC Holdings plc to “buy”.
• 9/25/2026 – Rezolute had its “market outperform” rating reaffirmed by Citigroup Inc..
• 9/25/2026 – Rezolute had its price target raised by HC Wainwright from $5.00 to $10.00. They now have a “buy” rating on the stock.
• 8/14/2026 – Rezolute was upgraded by Zacks Research from “strong sell” to “hold”.

Rezolute, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for rare and metabolic diseases. The company’s research is centered on therapies that address abnormal insulin activity and other conditions involving disrupted glucose regulation.

Rezolute’s leading product candidate is RZ358, an investigational monoclonal antibody designed to reduce the effects of excessive insulin. The therapy is being developed primarily for congenital hyperinsulinism, a rare disorder in which the pancreas produces too much insulin and causes potentially severe, recurrent hypoglycemia.